Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#141 / 200 Total
NFE - New Fortress Energy Inc - Stock Price Chart
TickerNFE [NASD]
CompanyNew Fortress Energy Inc
CountryUSA
IndustryUtilities - Regulated Gas
Market Cap2.08BEPS (ttm)-1.27
P/E-EPS this Y55.11%
Forward P/E-EPS next Y39.71%
PEG-EPS past 5Y5.11%
P/S0.88EPS next 5Y43.12%
P/B1.08EPS Q/Q-205.33%
Dividend1.32%Sales Q/Q-10.46%
Insider Own35.05%Inst Own65.58%
Insider Trans6.79%Inst Trans69.61%
Short Float21.84%EarningsMar 03/a
Analyst Recom2.00Target Price13.83
Avg Volume5.31M52W Range7.58 - 30.80
New Fortress Energy, Inc. is a holding company engaged in the management of integrated gas-to-power energy infrastructure. It funds, builds, and operates natural gas infrastructure and logistics to deliver energy solutions. The company was founded by Wesley Robert Edens on February 25, 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Guinta Christopher S.Chief Financial OfficerMar 13 '25Buy8.575,00042,850206,653Mar 13 12:15 PM
EDENS WESLEY RChief Executive OfficerMar 12 '25Buy9.07100,000907,00036,021,915Mar 12 12:22 PM
EDENS WESLEY RChief Executive OfficerMar 11 '25Buy8.77200,0001,754,00035,921,915Mar 11 01:21 PM
EDENS WESLEY RChief Executive OfficerOct 01 '24Buy8.635,793,74249,999,99335,721,915Oct 03 06:13 PM
CRBU - Caribou Biosciences Inc - Stock Price Chart
TickerCRBU [NASD, RUT]
CompanyCaribou Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap78.23MEPS (ttm)-1.65
P/E-EPS this Y-6.20%
Forward P/E-EPS next Y1.86%
PEG-EPS past 5Y-33.41%
P/S7.83EPS next 5Y-4.17%
P/B0.31EPS Q/Q0.23%
Dividend-Sales Q/Q-41.62%
Insider Own13.11%Inst Own58.73%
Insider Trans0.22%Inst Trans7.14%
Short Float10.92%EarningsMar 10/a
Analyst Recom1.25Target Price12.00
Avg Volume1.24M52W Range0.88 - 5.15
Mar-10-25 05:15PM Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-18-25 04:05PM Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.19%
05:45AM Shareholders of Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Feb-07-25 05:45AM Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-31-25 05:45AM Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CRBU (PR Newswire) +9.16%
Jan-24-25 05:45AM Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-17-25 05:45AM Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-14-25 05:45AM Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-12-25 07:05PM Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 (GlobeNewswire)
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haurwitz Rachel E.President and CEOMar 14 '25Buy1.0220,00020,4003,369,395Mar 17 08:01 AM
MCCLUNG BARBARA GChief Legal OfficerFeb 21 '25Sale1.353,5644,811443,502Feb 21 08:19 PM
Khan Ruhi AhmadChief Business OfficerFeb 21 '25Sale1.353,5644,81166,936Feb 21 08:19 PM
Kanner StevenChief Scientific OfficerFeb 21 '25Sale1.353,5644,811431,556Feb 21 08:18 PM
Ryali SriramChief Financial OfficerJan 29 '25Buy1.4217,36024,65117,360Jan 30 04:02 PM
ESPR - Esperion Therapeutics Inc - Stock Price Chart
TickerESPR [NASD, RUT]
CompanyEsperion Therapeutics Inc
CountryUSA
IndustryDrug Manufacturers - Specialty & Generic
Market Cap278.97MEPS (ttm)-0.27
P/E-EPS this Y83.04%
Forward P/E-EPS next Y-345.61%
PEG-EPS past 5Y40.11%
P/S0.84EPS next 5Y-
P/B-EPS Q/Q78.26%
Dividend-Sales Q/Q114.30%
Insider Own1.76%Inst Own65.77%
Insider Trans-1.07%Inst Trans-0.01%
Short Float14.87%EarningsMar 04/b
Analyst Recom1.62Target Price6.62
Avg Volume4.23M52W Range1.42 - 3.94
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Halladay BenjaminChief Financial OfficerMar 18 '25Sale1.483,5355,242481,710Mar 19 04:03 PM
Warren EricChief Commercial OfficerMar 18 '25Sale1.492,4333,618370,326Mar 19 04:02 PM
Koenig Sheldon L.President and CEOMar 18 '25Sale1.5013,04719,6231,571,962Mar 19 04:02 PM
Warren EricOfficerMar 18 '25Proposed Sale1.492,4333,618Mar 18 03:23 PM
Halladay BenjaminOfficerMar 18 '25Proposed Sale1.483,5355,243Mar 18 03:20 PM
OCEA - Ocean Biomedical Inc - Stock Price Chart
TickerOCEA [NASD]
CompanyOcean Biomedical Inc
CountryUSA
IndustryBiotechnology
Market Cap7.72MEPS (ttm)-0.84
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q62.02%
Dividend-Sales Q/Q-
Insider Own16.22%Inst Own2.62%
Insider Trans0.00%Inst Trans-39.70%
Short Float0.19%Earnings-
Analyst Recom1.00Target Price18.50
Avg Volume54.99M52W Range0.05 - 3.85
Mar-28-25 08:30AM Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China (GlobeNewswire) -18.46%
Feb-10-25 08:00AM Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development (GlobeNewswire) +11.36%
Jan-29-25 08:30AM Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway (GlobeNewswire) -26.33%
Nov-22-24 04:45PM Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
Oct-22-24 04:45PM Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter (GlobeNewswire)
Oct-15-24 07:30AM Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. (GlobeNewswire) +18.27%
Oct-01-24 08:01AM Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses (GlobeNewswire) -5.10%
Aug-27-24 08:01AM Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms (GlobeNewswire) -7.24%
Aug-23-24 04:30PM Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire) -5.61%
Jun-12-24 07:46AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -10.00%
Ocean Biomedical, Inc. is a biopharmaceutical company. It engages in the business of discovering and developing therapeutic products in oncology, fibrosis, infectious diseases and inflammation. The company was founded by Chirinjeev Kathuria in June 2021 and is headquartered in Providence, RI.
LYRA - Lyra Therapeutics Inc - Stock Price Chart
TickerLYRA [NASD, RUT]
CompanyLyra Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap7.91MEPS (ttm)-1.44
P/E-EPS this Y42.42%
Forward P/E-EPS next Y-2.02%
PEG-EPS past 5Y-2.22%
P/S5.17EPS next 5Y21.95%
P/B0.68EPS Q/Q36.73%
Dividend-Sales Q/Q43.15%
Insider Own16.73%Inst Own37.88%
Insider Trans0.00%Inst Trans-27.62%
Short Float4.38%EarningsMar 13/a
Analyst Recom3.00Target Price2.00
Avg Volume1.01M52W Range0.13 - 6.36
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.
DHAI - DIH Holding US Inc - Stock Price Chart
TickerDHAI [NASD]
CompanyDIH Holding US Inc
CountryUSA
IndustryMedical Devices
Market Cap10.63MEPS (ttm)-0.32
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.15EPS next 5Y-
P/B-EPS Q/Q-190.57%
Dividend-Sales Q/Q-20.60%
Insider Own50.67%Inst Own2.07%
Insider Trans0.00%Inst Trans-3.91%
Short Float0.65%Earnings-
Analyst Recom-Target Price-
Avg Volume539.62K52W Range0.23 - 3.67
DIH Holding US, Inc. provides global robotics and virtual reality technology services. It serves the healthcare industry. The company was founded by Jason Chen in 2007 and is headquartered in Norwell, MA.
VERV - Verve Therapeutics Inc - Stock Price Chart
TickerVERV [NASD, RUT]
CompanyVerve Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap367.17MEPS (ttm)-2.35
P/E-EPS this Y-13.49%
Forward P/E-EPS next Y-0.85%
PEG-EPS past 5Y-42.43%
P/S11.36EPS next 5Y5.30%
P/B0.74EPS Q/Q17.00%
Dividend-Sales Q/Q154.28%
Insider Own25.47%Inst Own69.92%
Insider Trans-0.00%Inst Trans5.77%
Short Float23.08%EarningsFeb 27/b
Analyst Recom1.40Target Price22.25
Avg Volume1.44M52W Range4.30 - 13.24
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dorval AllisonChief Financial OfficerDec 02 '24Sale5.645553,1305,380Dec 03 04:30 PM
Kathiresan SekarChief Executive OfficerJun 28 '24Option Exercise2.8730,00086,100351,128Jul 02 07:30 AM
Ashe Andrew D.See RemarksMay 14 '24Buy6.2676,000475,760342,509May 15 05:30 PM
ENGN - enGene Holdings Inc - Stock Price Chart
TickerENGN [NASD]
CompanyenGene Holdings Inc
CountryCanada
IndustryBiotechnology
Market Cap220.73MEPS (ttm)-1.52
P/E-EPS this Y-37.72%
Forward P/E-EPS next Y-10.46%
PEG-EPS past 5Y-
P/S-EPS next 5Y-8.08%
P/B0.88EPS Q/Q-4.59%
Dividend-Sales Q/Q-
Insider Own56.52%Inst Own42.01%
Insider Trans3.72%Inst Trans-23.18%
Short Float0.19%EarningsMar 10/a
Analyst Recom1.27Target Price24.00
Avg Volume94.51K52W Range4.20 - 17.54
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Forbion Growth Opportunities F10% OwnerOct 30 '24Buy8.90561,7974,999,9933,032,430Nov 01 04:15 PM
Forbion Growth Opportunities F10% OwnerSep 30 '24Buy6.34341,3322,163,3622,400,791Oct 18 04:15 PM
Forbion Growth Opportunities F10% OwnerSep 27 '24Buy5.9741,639248,6992,059,459Oct 18 04:15 PM
Forbion Growth Opportunities F10% OwnerOct 01 '24Buy6.4435,279227,1582,436,070Oct 18 04:15 PM
Forbion Growth Opportunities F10% OwnerOct 07 '24Buy6.5511,84477,5312,469,833Oct 18 04:15 PM
ADD - Color Star Technology Co Ltd - Stock Price Chart
TickerADD [NASD]
CompanyColor Star Technology Co Ltd
CountryUSA
IndustryEntertainment
Market Cap16.70MEPS (ttm)-0.97
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y62.76%
P/S5.90EPS next 5Y-
P/B2.05EPS Q/Q-409.55%
Dividend-Sales Q/Q28.55%
Insider Own5.06%Inst Own0.29%
Insider Trans0.00%Inst Trans0.38%
Short Float0.47%Earnings-
Analyst Recom-Target Price-
Avg Volume1.17M52W Range0.67 - 185.00
Color Star Technology Co., Ltd. is an entertainment technology company, which engages in the application of technology and artificial intelligence in the entertainment industry. The firm offers a professional artist training platform that features exclusive content and live interaction. Its courses are focused on music, sports, animation, painting, calligraphy, film and television, and life skills. The company was founded in 2002 and is headquartered in New York, NY.
XTIA - XTI Aerospace Inc - Stock Price Chart
TickerXTIA [NASD]
CompanyXTI Aerospace Inc
CountryUSA
IndustryAerospace & Defense
Market Cap3.87MEPS (ttm)-
P/E-EPS this Y94.66%
Forward P/E-EPS next Y52.06%
PEG-EPS past 5Y91.71%
P/S-EPS next 5Y72.83%
P/B0.84EPS Q/Q99.28%
Dividend-Sales Q/Q-55.37%
Insider Own9.17%Inst Own0.44%
Insider Trans0.00%Inst Trans498.12%
Short Float14.72%EarningsFeb 26
Analyst Recom1.00Target Price13.50
Avg Volume817.83K52W Range1.06 - 1270.00
XTI Aerospace, Inc. engages in the provision of aircraft manufacturing. It primarily focuses on the light and mid-size business aircraft market. The company was founded in April 1999 and is headquartered in Englewood, CO.
11011121314151617181920